2X Long Berkshire (2BRK) | Stock Overview & Key Data
2X Long Berkshire Hathaway Mutual Fund | Micro-cap
2X Long Berkshire Hathaway Mutual Fund | Micro-cap
2X Long Berkshire Performance Comparison
Stock Range
Today's Range
Low: €8.38
High: €8.51
on September 23, 2025
52 Week Range
Low: €7.55
High: €11.68
on August 8, 2025
on March 26, 2025
All-Time High: €11.68 on March 24, 2025
Explore how other NL stocks compare to their 52-week ranges: View NL Market 52-Week Insights
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Returns and Earnings
Return on Assets (TTM)
N/A
Return on Equity (TTM)
N/A
EBITDA
€0
Net Income (TTM)
€0
Growth
Revenue (TTM)
Revenue Per Share (TTM)
N/A
Quarterly Revenue Growth (YoY)
N/A
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| 2X Long Berkshire 2BRK | N/A Micro-cap | 4.03% | 4.29% | -0.12% | -24.29% | -6.48% | -1.16% | 83.80% | 83.80% |
| UBS AG, London 0022U | N/A Micro-cap | 0.09% | 0.47% | 3.30% | 3.04% | 3.93% | 8.73% | 24.56% | 24.56% |
| GLDFP 100PRO0825U 0110U | N/A Micro-cap | 0.08% | 0.35% | 1.16% | 2.41% | 2.94% | 6.55% | 22.72% | 22.72% |
| MSCIW 103PRO0226U 0119U | N/A Micro-cap | -0.02% | -0.02% | 1.62% | 3.24% | 4.61% | 6.94% | 19.67% | 19.67% |
| Ark Genomic 1ARKG | N/A Micro-cap | 8.94% | 11.43% | 16.77% | 6.56% | -1.02% | 3.72% | -96.66% | -96.93% |
| 1Ark Innovation 1ARKK | N/A Micro-cap | 6.57% | 10.36% | 20.32% | 44.57% | 28.62% | 68.78% | 49.20% | 153.74% |
Ownership & Short Interest
Insider Ownership
N/A
Institutional Ownership
N/A
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
35
Average 90-Day Volume
274
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is 2BRK's 52-week high and low?
- In the last 52 weeks, 2X Long Berkshire reached a high of €11.68 (on March 26, 2025) and a low of €7.55 (on August 8, 2025).
- What is the market cap and P/E ratio for 2BRK?
- Curious about 2X Long Berkshire's size and valuation? Its market capitalization stands at N/A. When it comes to valuation, the P/E ratio (trailing twelve months) is N/A, and the forward P/E (looking ahead) is N/A.
- Does 2BRK pay dividends? If so, what's the yield?
- As for dividends, 2X Long Berkshire isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are 2X Long Berkshire's main competitors or similar companies to consider before investing?
When looking at 2X Long Berkshire, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return UBS AG, London
0022UN/A N/A N/A 8.73% 24.56% GLDFP 100PRO0825U
0110UN/A N/A N/A 6.55% 22.72% MSCIW 103PRO0226U
0119UN/A N/A N/A 6.94% 19.67% Ark Genomic
1ARKGN/A N/A N/A 3.72% -96.66% 1Ark Innovation
1ARKKN/A N/A N/A 68.78% 49.20% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for 2X Long Berkshire Hathaway Mutual Fund? (e.g., ROE, Debt/Equity)
- To get a sense of 2X Long Berkshire's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is N/A, the Debt to Equity ratio from the most recent quarter is N/A, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for 2BRK?
- Looking at 2X Long Berkshire's growth, its revenue over the trailing twelve months (TTM) was €0. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.
- How much of 2BRK stock is held by insiders and institutions?
- Wondering who owns 2X Long Berkshire stock? Company insiders (like executives and directors) hold about N/A of the shares, while institutional investors (such as mutual funds and pension funds) own approximately N/A.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.